Global Gene Therapy Market Trends to 2025

Dublin, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( has announced the addition of the "Gene Therapy Market, 2015 - 2025" report to their offering.

The "Gene Therapy Market, 2015-2025" report provides an extensive study on the marketed and pipeline gene therapies. A lot of research has been carried out in this field for over a decade but there are only five approved therapies (four available in Asian markets; one approved in the EU). There are many promising therapies which are currently being developed worldwide; the approach is likely to result in several commercial success stories in the foreseen future. The report covers various aspects, such as key players, marketed gene therapy products, products in clinical / pre-clinical research, associated ethical issues, likely future developments and upcoming opportunities for a variety of stakeholders.

Several disorders that arise inside the body are a result of either a direct genetic aberration or a dysfunctional/non-functional protein. The attempt to use nucleic acids to correct or delete the genes causing a particular disease is known as gene therapy. Although gene therapy has not contributed significantly to the global pharmaceutical market yet, it is anticipated to grow at a fast pace over the next decade.

Gendicine, developed by SiBiono GeneTech, was the foremost gene therapy that entered market in 2004 in China. Since then four more therapies have received approval in China, Philippines, Russia and the EU. This number for approved / marketed therapies seems weak at present; however, the strong and highly populated pipeline holds tremendous potential. There are 12 gene therapies in late stage of clinical development for the treatment of cancer, ocular and cardiovascular disorders.

There are several concerns that remain to be answered; examples include insertional mutagenesis, treatment of multigene disorders, curbing the risk of immune reactions, eugenics, high cost of therapy and ethical concerns related to making alterations at the genetic level. Despite this, gene therapy does offer a ray of hope for patients who either have no treatment options or show no benefits with drugs that are currently available. Such a benefit far outweighs any disadvantages that may be associated with this upcoming therapeutic field.

There is a lot of research underway for the first generation of controlled gene therapy, gene expression cassettes which deliver optimised gene expression and vectors which minimise the risk of immunogenicity. These research efforts have received strong support from various venture capital firms and institutional investors. With the expected launch of several new gene therapies in the US and EU, we expect the market to witness significant growth in the coming decade.

As pharma companies continue to expand their research programs in this area, one of the key objectives outlined for this report is to understand the future potential of the market.

Example Highlights

- Gendicine became the first approved gene therapy in China in 2004. So far, there have been three more marketed gene therapies: Rexin-G, Oncorine and Neovasculgen. All of these have been made commercially available in Asian countries. Glybera was the first gene therapy to be approved in the EU in 2012.
- We have identified a total of 483 gene therapy molecules in the marketed and the clinical pipeline which are designed for different therapeutic areas. Except a few which are in advanced stages of development, majority of the gene therapies are in early development stages.
- There are several challenges and ethical issues associated with this field; germline gene therapy is one of the important issues. The existing gene therapies use somatic cells. However, research is in progress to introduce germline gene therapy in the market since some of the serious inherited genetic diseases, such as Lecsh-Nyhan Syndrome, can only be treated by germline gene therapy.
- There has been a growing interest from Venture Capital firms in the gene therapy space. In fact, in 2013 / 2014, several companies were involved in investment in gene therapies; during January 2013 to April 2014, a total USD 600 million was raised by the US companies alone. This activity is likely to increase further and will help companies, especially start-ups, drive their respective products to commercialisation.
- We expect the gene therapy market to be worth USD 11 billion by 2025, representing a healthy annual growth rate of 48.9%; specific therapies such as Prostavac, ProstAtak and TroVax are likely to achieve blockbuster status.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Viral and Non-Viral Vectors

5. Pipeline of Gene Therapy

6. Marketed Gene Therapies and Applications

7. Gene Therapy: Pipeline Products

8. Promising Therapeutics Areas

9. Gene Therapy: Additional Considerations

10. Conclusion

11. Interview Transcripts

12. Appendix 1: Tabulated Data

13. Appendix 2: List of Companies and Organisations


- AAV Life
- Abeona Therapeutics
- ActoGenix
- Adaptimmune
- Aduro Biotech
- Advantagene
- Advaxis
- Aeras
- Alphavax
- Amgen
- AmphliPhi Biosciences
- Amsterdam Molecular Therapeutics
- Anaeropharma Science
- AnGes MG
- Applied Genetic Technologies Corp
- Asklepios BioPharmaceutical Inc.
- Astellas Pharma
- Audentes Therapeutics
- Avalanche Biotechnologies
- AveXis Inc
- Bavarian Nordic
- Baxter Healthcare Corporation
- Bellicum Pharmaceuticals
- Benitec BioPharma
- BioCancell
- Bioheart
- Biomics Biotechnologies
- Biontech
- Biovex
- Bluebird Bio
- BN ImmunoTherapeutics
- Calimmune
- Cardium Therapeutics
- Cell Therapy Catapult
- Celladon Corporation
- Ceregene
- ChiesiFarmaceutici
- ClinDatrix
- Cold Genesys, Inc.
- Crucell
- CytRx Corporation
- Daiichi Sankyo
- Diamyd Inc.
- Digna Biotech S.L.
- DNAtrix
- DNAVEC Corporation
- EGEN, Inc.
- Emergent Biosolutions
- Enzo Biochem
- Epeius Biotechnologies
- Errant Gene Therapeutics
- Etubics Corporation
- FKD Therapies Oy
- Fondazione Telethon
- Genable Technologies
- Gene Medicine Japan
- GeneCure Biotechnologies
- Genelux Corporation
- GeneOne Life Sciences
- GeneSight Biologics
- Genethon
- Genexine
- Genprex
- GenVec
- Genzyme
- GeoVax Inc.
- GlaxoSmithKline
- GlobeImmune
- Guangzhou DoublleBioproducts
- Gradalis Inc.
- Heat Biologics
- Helica Labs
- Herantis Pharma
- Ichor Medical Systems
- Imaxio
- Immune Design
- Inovio Pharmaceuticals
- Invivodata
- Ion Channel Innovations
- IrsiCaixa
- Isis Innovation
- Jennerex Biotherapeutics
- Juventas Therapeutics, Inc.
- Kolon Life Science
- Marsala Biotech
- Medison Pharma
- Medigen Biotechnology Corporation
- Memgen Bio
- Merck
- Milo Biotechnology
- MiroVAX
- Mitsubishi Tanabe
- MolMed S.p.A
- Mologen AG
- Momotaro-Gene Inc
- MultiGene Vascular Systems
- NanoCor Therapeutics
- Neurotech Pharmaceuticals
- Newlink Genetics Corporation
- Nightstar
- Novartis
- Oncolys BioPharma
- OncoSec Medical Incorporated
- Oncos Therapeutics
- Orca Therapeutics
- Oxford BioMedica
- Quintiles
- Pacific-Link Consulting
- Paragon Biomedical
- Pfizer
- PNP Therapeutics
- Profectus Biosciences
- Regen BioPharma
- Regeneron
- RegenX Biosciences
- ReiThera Sri
- REPLIcor
- Roche
- SanBio
- Sangamo Biosciences
- Sanofi
- Scancell Ltd
- Schering AG
- Shanghai Sunway Biotech
- SiBiono GeneTech
- SillaJen
- SironRX Therapeutics
- Spark Therapeutics
- SynerGene Therapeutics
- Tacere Therapeutics
- Takara Bio
- Theradex
- Theravectys S.A.
- Tocagen
- Transgene
- Treeway
- uniQure
- Vascular Biogenics
- Vaximm GmbH
- VCN Biosciences
- Vical
- ViroMed
- VIRxSYS Corporation
- Voyager Therapeutics
- Virttu Biologics
- Ziopharm

For more information visit


Contact Data